AiCuris was created in 2006 as a spin-out of Bayer’s anti-infective division and is backed by the Strüngmann family office as lead investor and other private investors well known in Germany. We develop innovative drugs against severe and life-threatening infectious diseases. By targeting indications with high medical need, as well as preparing for pandemic and resistance emergencies, we focus on markets where no efficient solution is available and bring novel approaches into a long-underserved sector.